Healey ALS MyMatch

Overview

The goal of the Healey ALS MyMatch program is to accelerate the development of new therapies for ALS. ALS MyMatch is a series of early-phase (Phase 1b/2a) clinical trials. These trials assess a range of investigational products, including experimental and repurposed medications, cell-based therapies, gene-targeted therapies, devices, etc. Participants are matched to specific trials based on their own genetic and biofluid biomarkers, placing participants at the center of the research process. By prioritizing high quality biomarker data in early-phase clinical trials, ALS MyMatch paves the way for faster advancements in treatment.

Launched in 2025, this collaborative ALS MyMatch initiative was made possible through generous philanthropic support to the Sean M. Healey & AMG Center for ALS at Mass General Brigham. ALS MyMatch trials are conducted at multiple trial-ready U.S. ALS research and clinical care centers selected from the Network of Excellence for ALS (NEALS). Data generated from successful ALS MyMatch trials will inform future late phase clinical trial design via the HEALEY ALS Platform Trial or a standalone Phase 2/3 trial.

ALS MyMatch Trials

Future trials will be added as new investigational products become available.

• ACACIA Trial of Oral Digoxin – Enrollment Complete
  Visit ClinicalTrials.gov for information about study details and site locations (NCT07047209).

Watch a webinar about the ACACIA Trial

Researcher Resources

The Sean M. Healey & AMG Center for ALS is seeking applications of experimental therapies for inclusion in this clinical trial initiative on a rolling basis. ALS MyMatch trials are best suited for therapies focused on biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding. We invite investigators from both academia and industry to apply for consideration in ALS MyMatch.

This program is not for Phase 1 healthy volunteer studies.

Please consider applying to the HEALEY ALS Platform Trial if the primary objective is a clinical efficacy trial in ALS.

Review Criteria

1. Relevance: Assesses whether preclinical or human data support the target and therapeutic approach in ALS.
2. Impact: Determines whether a successful trial would meaningfully advance ALS therapeutic development and support future drug development.
3. Fit & Readiness for MyMatch: Evaluates manufacturing readiness, drug/placebo availability, safety/toxicology data, regulatory interactions, IND status, and any human trial experience.
4. Biomarkers: Identifies availability and strength of entry, endpoint, or target‑engagement biomarkers for selection, stratification, or mechanistic assessment.

Confidential Disclosure Agreements (CDAs)

Confidential Disclosure Agreements (CDAs) are executed between Mass General Brigham (on behalf of the Review Committee members) and the institution or company before the Healey ALS MyMatch Therapy Application Form is submitted.

Download the CDA template (Word document)and submit completed CDA form to Healeyamgcenterforals@mgh.harvard.edu.

Application Form

Download the application form (PDF) and submit your completed application and CDA to Healeyamgcenterforals@mgh.harvard.edu.

Publication Submission Form

Download the publication submission form (PDF) and submit the completed form along with your publication to Healeyamgcenterforals@mgh.harvard.edu.

Informational Webinar

This informational webinar is for stakeholders developing therapies in ALS.

We invite company representatives and academic investigators with therapies in development for ALS to view the recording of the informational webinar we hosted on Thursday, April 10, 2025, to learn about ALS MyMatch and the therapy application process. Please contact us at Healeyamgcenterforals@mgh.harvard.edu. for all inquiries.

Watch the webinar